Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...

Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...

Edwards Lifesciences' Sapien 3 is actually already on the market—it received FDA approval in June 2015 for use in high-risk patients with severe, symptomatic aortic stenosis. But another indication is ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

and the upcoming SAPIEN 3 mitral replacement system. The company has been gaining market shares in TMTT market. As such, I project 15% revenue growth. Surgical Structural Heart: I forecast the ...

Sapien, a platform to create “autonomous coworkers” for finance professionals, officially launched on Tuesday. The founders announced an $8.7 million seed fund for the startup, which touts its ...

U.S. Recession Signal Flares From 10-Year and 3-Month Yield Spread Sapien, a startup that incentivizes people to supply all sorts of data for use in AI, has raised $10.5 million in seed funding ...

The company remains pleased with the performance of its SAPIEN 3 Ultra RESILIA, the leading platform in the United States and Japan. In Europe, EW continues to introduce the SAPIEN 3 Ultra RESILIA ...